Response by Herrmann et al to Letter Regarding Article, “Vascular Toxicities of Cancer Therapies: The Old and the New—An Evolving Avenue”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We deeply appreciate the comments by Giuseppina and Giovanni emphasizing an important point: the overlap between disease conditions and chemotherapeutic agents with regard to vascular toxicities. In our article,1 we alluded to the parallels among vascular endothelial growth factor signaling pathway inhibitor effects, peripartum cardiomyopathy, and preeclampsia. This aspect was outlined in even greater detail in an article by Bellinger et al2 in this journal. The current perception is that the placental release of soluble fms-related tyrosine kinase 1 and endoglin leads to vascular endothelial growth factor signaling pathway and transforming growth factor-beta signaling pathway inhibition with profound effects on endothelial cells and pericytes. The interplay of those 2 cell populations is …